MHC-II-positive cells in MI6 tumours were nearly exclusively CD45+ cells (95 ± 1.7%), half of which were macrophages (CD11b+F4/80+: 52.5 ± 7.8%), independent of treatment, and one-third of which were CD11b−F4/80− cells (33.3 ± 5.5%) (Figure S7). Here, PTPRC is linked to neoplasm.